China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

MDxHealth reported on Thursday that its third quarter revenues rose 23 percent year over year, largely due to a 23 percent increase in services revenues during the quarter.

Danaher on Thursday reported a 23 percent year-over-year increase in third quarter revenues, which included a rise of nearly 25 percent in life sciences revenues and of nearly 30 percent in diagnostics revenues.

BioMérieux reported on Thursday that its third quarter revenues grew 11 percent year over year, driven by growth across its application areas.

Cell fitness has been identified as a way of predicting health outcomes in COVID patients, according to a University of Queensland study.

Abbott reported Wednesday that its third quarter Diagnostics business revenues rose 48 percent year over year, mainly driven by sales in its Core Laboratory and Rapid Diagnostics businesses.

Roche said on Wednesday that its diagnostics division revenues grew 38 percent year over year, or 39 percent at constant exchange rates, in the first nine months of 2021, due to high demand for COVID-19 tests, recovery in the base business, and the launch of new diagnostic platforms.

October 19, 2021, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (“Mindray”) (300760.SZ) released the third quarter report: sale in the third quarter was 6.613 billion CNY, up 20.25% year on year.

Skin disease diagnostics company Castle Biosciences said on Tuesday that it has signed a definitive agreement to acquire Cernostics, a privately held firm that specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.

The US Food and Drug Administration last week granted Emergency Use Authorization for Lighthouse Lab Services' CovidNow SARS-CoV-2 Assay.

On October 18, 2021, ACROBiosystems listed on Shenzhen Stock Exchange (SZSE) ChiNext. The issue price is RMB 112.5 per share, and the opening price is RMB 198 per share. The total amount of funds to be raised is 2.25 billion yuan.